Martini, D., Evans, S., Goyal, S., Liu, Y., Anders Olsen, T., Magod, B., Brown, J., Yantorni, L., Russler, G., Caulfield, S., Goldman, J., Nazha, B., Harris, W., Master, V., Kucuk, O., Carthon, B., & Bilen, M. (n.d.). 637 Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI). Journal for immunotherapy of cancer, 8, A380–A381. http://access.bl.uk/ark:/81055/vdc_100144719175.0x00000f